Jason Frazier brings over 20 years of cancer research and platform technology development to Presage. At Presage, he has led multiple efforts in the design and implementation of the CIVO® platform, including the development and manufacturing of CIVO GLO microdose tracking technology. He oversees Presage’s laboratory operations and leads strategic research and development growth initiatives. Prior to joining Presage, he worked in biotech and Pharma, including Merck’s Rosetta Inpharmatics in Seattle. At Rosetta, he worked to develop High Throughput Screening platforms for target discovery, biomarker discovery, and target validation programs. Jason holds a degree in Biochemistry from Western Washington University.